Stockscreener 앱 받기
9.46
2.17%
-0.21
전일 마감가:
$9.67
열려 있는:
$9.6
하루 거래량:
133.01K
Relative Volume:
0.47
시가총액:
$277.95M
수익:
$1.78M
순이익/손실:
$-151.77M
주가수익비율:
-1.6316
EPS:
-5.7981
순현금흐름:
$-79.40M
1주 성능:
-10.67%
1개월 성능:
+27.32%
6개월 성능:
+15.37%
1년 성능:
-30.13%
1일 변동 폭
$9.08
$9.73
1주일 범위
$9.08
$10.84
52주 변동 폭
$5.60
$14.56
Cartesian Therapeutics Inc Stock (RNAC) Company Profile
명칭
Cartesian Therapeutics Inc
전화
301-348-8698
주소
7495 NEW HORIZON WAY, FREDERICK
Compare RNAC vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
RNAC
Cartesian Therapeutics Inc
|
9.46 | 277.95M | 1.78M | -151.77M | -79.40M | -5.7981 |
VRTX
Vertex Pharmaceuticals Inc
|
485.39 | 123.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
664.52 | 69.67B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.62 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
298.76 | 39.89B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
186.88 | 39.73B | 742.00K | -1.37B | -1.07B | -7.0731 |
Cartesian Therapeutics Inc Stock (RNAC) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-09 | 업그레이드 | Cantor Fitzgerald | Neutral → Overweight |
| 2025-07-09 | 개시 | Wedbush | Outperform |
| 2024-12-19 | 개시 | BTIG Research | Buy |
| 2024-08-06 | 개시 | TD Cowen | Buy |
| 2024-07-02 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2024-06-04 | 개시 | Oppenheimer | Outperform |
| 2024-05-24 | 개시 | Mizuho | Buy |
| 2024-04-23 | 재확인 | H.C. Wainwright | Buy |
| 2024-04-23 | 개시 | Leerink Partners | Outperform |
| 2023-08-18 | 다운그레이드 | SVB Securities | Outperform → Market Perform |
| 2022-06-14 | 재확인 | Needham | Buy |
| 2022-06-06 | 개시 | SVB Leerink | Outperform |
| 2021-06-15 | 개시 | BTIG Research | Buy |
| 2021-01-26 | 업그레이드 | Mizuho | Neutral → Buy |
| 2020-10-01 | 다운그레이드 | Mizuho | Buy → Neutral |
| 2020-10-01 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2020-06-12 | 다운그레이드 | Stifel | Buy → Hold |
| 2020-04-28 | 개시 | H.C. Wainwright | Buy |
| 2020-01-29 | 개시 | Cantor Fitzgerald | Overweight |
| 2020-01-21 | 개시 | William Blair | Outperform |
| 2018-06-27 | 개시 | Janney | Buy |
| 2017-03-30 | 재확인 | UBS | Buy |
모두보기
Cartesian Therapeutics Inc 주식(RNAC)의 최신 뉴스
Cartesian Therapeutics Inc. : RNAC - 24/7 Wall St.
Emerging Therapies Transforming the Myasthenia Gravis Market by DelveInsight | Sanofi, Cartesian Therapeutics, Takeda, UCB Biopharma, Roche, Janssen R&D, Immunovant Sciences GmbH, Argenx-Halozyme - Barchart.com
Wedbush Initiates Coverage of Cartesian Therapeutics (RNAC) with Outperform Recommendation - MSN
Cartesian Therapeutics Announces New Employment Inducement Grants - Yahoo Finance
Cartesian offers 8 new hires stock options worth 238,700 shares - Stock Titan
BTIG Maintains Cartesian Therapeutics(RNAC.US) With Buy Rating, Maintains Target Price $44 - Moomoo
RNACCartesian Therapeutics Inc Latest SEC Filings - Finviz
Cartesian Therapeutics (RNAC) Q1 2026 Earnings: Wider-than-Expected Loss as Clinical-Stage Pipeline AdvancesOne-Time Gain Impact - dars.gov.et
Price to earnings forward of Cartesian Therapeutics, Inc. – NASDAQ:RNAC - TradingView
Cabaletta Bio: The Market Sold The EULAR News, I'm Buying (NASDAQ:CABA) - Seeking Alpha
RNAC Forecast — Price Target — Prediction for 2027 - TradingView
Cartesian Therapeutics, Inc. Actuals & Estimates (NASDAQ:RNAC) - TradingView
Enterprise value to EBIT forward of Cartesian Therapeutics, Inc. – NASDAQ:RNAC - TradingView
Price to sales forward of Cartesian Therapeutics, Inc. – GETTEX:1S70 - TradingView
Price to book forward of Cartesian Therapeutics, Inc. – GETTEX:1S70 - TradingView
Cartesian Therapeutics Inc (RNAC) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Cartesian Therapeutics Shareholders Back Directors and Governance Measures - The Globe and Mail
Cartesian Therapeutics Inc (RNAC) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Cartesian Therapeutics Inc (RNAC) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Cartesian Therapeutics Inc (RNAC) Valuation: PE, PB & Fair Value Analysis - TradingKey
Cartesian Therapeutics Inc (RNAC) Institutional Confidence - TradingKey
Shareholders of Cartesian Therapeutics (NASDAQ: RNAC) back board, pay and auditor - Stock Titan
Cartesian Therapeutics Inc (RNAC) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Cartesian Therapeutics Inc (RNAC) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Cartesian Therapeutics Inc (RNAC) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Cartesian Therapeutics Inc (RNAC) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Cartesian Therapeutics Inc PE Ratio (TTM) & PE Ratio (TTM) ChartsRNAC - GuruFocus
Cartesian Therapeutics (RNAC) Slides 7.2% as Support Nears $8.38Corrective Wave - newsline.com
RNAC SEC FilingsCartesian 10-K, 10-Q, 8-K Forms - Stock Titan
New partnership gives Cartesian Therapeutics another shot at autoimmune disease market - MSN
RNAC Q1 2026 Earnings: Disappointing EPS Miss Yet Stock Surges 18%Earnings Weakness Phase - newsline.com
Cartesian Therapeutics Announces New Employment Inducement Grant - The Manila Times
New hire at Cartesian gets 6,100 stock options vesting to 2030 - Stock Titan
Cartesian climbs on licensing deal with WestGene for CAR-T therapies - MSN
RNAC: Directors elected and all proposals passed with strong support; no stockholder questions submitted - TradingView
Cartesian Therapeutics, Inc. (RNAC) soars 10.3%: Is further upside left in the stock? - MSN
Cartesian Eyes Multiple 2026-2027 Readouts As Descartes-08 Advances Toward Potential BLA - RTTNews
RNAC Reiterated by Wedbush -- Price Target Maintained at $38.00 - GuruFocus
RNAC Reiterated by BTIG -- Price Target Maintained at $44.00 - GuruFocus
Analysts Offer Insights on Healthcare Companies: Tango Therapeutics (TNGX), Cartesian Therapeutics (RNAC) and Abbott Laboratories (ABT) - The Globe and Mail
Mizuho Securities Maintains Cartesian Therapeutics(RNAC.US) With Buy Rating, Announces Target Price $40 - Moomoo
Morgan Stanley Smith Barney (RNAC) lists exercises, vesting and a 3,924-share resale - Stock Titan
RNAC Reiterated by Needham -- Price Target Maintained at $40 - GuruFocus
Cartesian Therapeutics (RNAC) Shares Surge 30% on Licensing Agre - GuruFocus
WestGene Biopharma to collaborate with Cartesian Therapeutics on in vivo CAR-T for autoimmune disease - Traders Union
Cartesian partners with WestGene for in vivo autoimmune CAR-T - grafa.com
Cartesian inks licensing deal with WestGene (RNAC:NASDAQ) - Seeking Alpha
Cartesian Therapeutics stock jumps on WestGene partnership deal - Investing.com UK
Cartesian Therapeutics stock jumps on WestGene partnership deal By Investing.com - Investing.com Australia
Cartesian Therapeutics Announces In Vivo CAR-T Licensing Alliance - TipRanks
Cartesian strikes licensing agreement with WestGene - The Pharma Letter
Cartesian Therapeutics Inc (RNAC) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.64%
자본화:
|
볼륨(24시간):